Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. Apr 4 2013;368(14):1279-1290. PMID: 23432189. 134. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. Jun 21 2018;378(25):e34. PMID: 29897866. 135. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and meta- analyses. J Hypertens. Jul 2015;33(7):1321-1341. PMID: 26039526. 136. Wright JT, Jr., Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. Jama. Apr 6 2005;293(13):1595-1608. PMID: 15811979. 137. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT). JAMA. Dec 18 2002;288(23):2981-2997. PMID: 12479763. 138. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid- lowering treatment to prevent heart attack trial. Hypertension. Sep 2006;48(3):374-384. PMID: 16864749. 139. Julius S, Alderman MH, Beevers G, et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The LIFE study. J Am Coll Cardiol. Mar 17 2004;43(6):1047-1055. PMID: 15028365. 140. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. Jama. Jun 6 2001;285(21):2719-2728. PMID: 11386927. 141. Rahman M, Ford CE, Cutler JA, et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT) participants by baseline estimated GFR. 